CytomX Therapeutics (NASDAQ:CTMX) saw its stock price plummet by 7.80% in early trading on Thursday, following a significant downgrade in analyst forecasts for the company's future performance. The sharp decline reflects growing concerns among investors about the biotech firm's financial outlook and growth prospects.

The selloff was triggered by a substantial revision to CytomX's 2026 forecasts. Analysts have dramatically cut their revenue expectations from $50 million to just $31 million, representing a painful 73% decline in sales compared to the previous year. More alarmingly, the company is now projected to slip into loss-making territory, with analysts forecasting losses of $0.40 per share in 2026, compared to the earlier expectation of a $0.27 per share loss.

This pessimistic outlook stands in stark contrast to the broader industry trends. While the biopharmaceutical sector is anticipated to see revenue growth of 22% annually for the foreseeable future, CytomX is expected to experience a significant contraction. The company's projected annualized revenue decline of 65% by the end of 2026 marks a dramatic reversal from its 22% annual growth over the past five years. As investors digest this gloomy forecast, many are reassessing their positions in CytomX Therapeutics, leading to the observed sharp decline in stock price.